Neuroendocrine Tumors of the Appendix Are Probably Harmless Neoplasms Abstract #1484

Introduction: Appendiceal neuroendocrine tumors (aNETs) have a 5-year survival rate between 74% and 95% according to recent data from Cancer Registry of Norway and the United States, respectively. However, in the daily clinical practice one almost never encounters patients suffering from aNETs with distant metastasis or dying of the disease.
Aim(s): In order to resolve this contradiction, we performed a systematic search in PubMed.
Materials and methods: Systematic search was carried out using key words “appendix or appendiceal”, “carcinoid or neuroendocrine tumors”, “survival” and “registry or register”. We accessed the row data from Surveillance, Epidemiology and End Results Program (SEER) and received recent data from Cancer Registry of Norway (CRN).
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Maike Nieser
Keywords: NET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1490 Even Malignant Appendiceal Neuroendocrine Tumors Exhibit No Recurrent Chromosomal Alterations
Introduction: Neuroendocrine tumors (NETs) of the midgut are located in the ileum (iNET), caecum or appendix (aNET). Despite of the similar origin, NETs of the ileum and the appendix behave remarkably different. iNETs show high malignant potential, which manifests with early lymph node or liver metastases. Genetically, the loss of chromosome 18 (Ch18) in 60-74% of cases is the most frequent alteration in iNETs. aNETs are often incidental findings, rarely show metastases, and no chromosomal alterations are known.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Maike Nieser
Keywords: NET
#2279 Expression of FOXM1 in G3 Neuroendocrine Tumors (NET G3) and G3 Neuroendocrine Carcinomas (NEC G3) of the Pancreas and the Intestine
Introduction: G3 gastroenteropancreatic neuroendocrine tumors (G3 NET) and carcinomas (G3 NEC) differ considerably concerning their biological behavior and patients outcome. Whereas the WHO2017 classification for pancreatic NETs proposes a distinction of both groups using the Ki-67 proliferation marker (Klöppel et al. Reviews and Reports 2017), a useful marker for the subclassification of G3 intestinal NETs have not been recommended until now.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Franziska Briest
#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: NET G3, GEP-NEN, GI-NET
#562 Expression of Chromosome 18 Related Tumor Suppressor Proteins in Ileal Neuroendocrine Tumors
Introduction: The genetic alterations in ileal neuroendocrine tumors (iNETs) are poorly
characterized. The most frequent chromosomal aberration is the loss of one
chromosome 18 in iNETs, however, the relevance of this alteration is unclear.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr. Tobias Henopp
#565 Proliferative Activity is Not Associated with Tumor Aggressiveness in Ileal Neuroendocrine Tumors
Introduction: The accuracy of the new WHO grading system for neuroendocrine neoplasms has not yet been validated for ileal neuroendocrine tumors (iNETs).
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: MD Tobias Henopp